Treatment
Cytarabine clinical trials
We’re tracking 155 recruiting studies that include Cytarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Birmingham, AlabamaAges Up to 21 years - NCT05241093RecruitingPhase 2
HYML-122 plus cytarabine for FLT3-positive relapsed AML
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
Suzhou, JiangsuAges 18 years+ - NCT05365035RecruitingPhase 2
Phase 2 trial for high-risk blood cancers with timed chemo
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
Houston, TexasAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60 - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Orange, CaliforniaAges 18–75 - NCT06060782RecruitingPhase 1
Chemo combo for high-risk blood cancer transplant patients
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Zhuhai, GuangdongAges 18–65 - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18 - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT06434662RecruitingPhase 2
Combination therapy for relapsed or refractory AML
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06504459RecruitingPhase 2
Testing a drug combo for certain types of AML
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Miami, FloridaAges 18 years+ - NCT06533761RecruitingPhase 1
Eganelisib alone or with chemo for relapsed AML
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+ - NCT06621199RecruitingPhase 2
Three-drug combination for newly diagnosed AML in older adults
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hangzhou, ZhejiangAges 60–70 - NCT06621212RecruitingPhase 2
Combination therapy for relapsed or refractory AML
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
Hangzhou, ZhejiangAges 18 years+ - NCT06854003RecruitingPhase 2
Study of new drug combo for untreated mantle cell lymphoma
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Phoenix, ArizonaAges 18 years+ - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT07187193RecruitingPhase 2
Low-dose chemo plus thalidomide for untreated LCH
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
BeijingAges 18–70 - NCT07228273RecruitingPhase 2
A new drug combo for AML and high-risk MDS
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Portland, OregonAges 18–65 - NCT07232134RecruitingPhase 3
Treating AML in children with Down syndrome
This trial tests a treatment plan for children with Down syndrome who have been diagnosed with acute myeloid leukemia (AML) or a related bone marrow condition. The goal is to see how well the therapy works and to help guide doctors in choosing the best approach.
MoscowAges 1 day–18 years - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+
Common questions
- Are there clinical trials studying Cytarabine?
- Yes. Clin2 currently lists 155 recruiting studies that include Cytarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cytarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cytarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cytarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.